Head and Neck Cancer Clinical Trial
Official title:
Effect of Triple Pre-rehabilitation on Radiotherapy for Head and Neck Cancer Patients: a Randomized Controlled Trial
Verified date | November 2023 |
Source | Peking University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the intervention effect of triple pre-rehabilitation on head and neck cancer patients with radiotherapy, and process evaluation to further optimize the intervention program. The pre-rehabilitation intervention was develped previously based on the process of evidence-based-nursing, including interventions of nurtrtion, exercise, and psychology.
Status | Completed |
Enrollment | 87 |
Est. completion date | October 30, 2023 |
Est. primary completion date | July 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - 18= age < 75 years old - The pathological diagnosis of HNC included nasopharyngeal cancer, oral cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, salivary gland cancer; - Plan to receive radiotherapy - Basic communication skills - Volunteer to participate in this study. Exclusion Criteria: - Combined with other malignant tumors - Distant metastasis - Inability to measure body composition, such as metal in the body or inability to stand alone - With contraindications to exercise (such as cardiovascular and cerebrovascular diseases, respiratory diseases, etc) - Complicated with severe liver and kidney function damage - Previous diagnosis of other cancers - pregnant or lactation women. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin medical university cancer institute and hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Peking University | China International Medical Foundation |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Critical weight loss | Weight loss over 5% during radiotherapy | About 6 weeks | |
Secondary | Rate of adverse reactions of radiotherapy assessed by CTCAE v5.0 | Adverse reactions of radiotherapy | About 6 weeks | |
Secondary | Physical performance | Physical performance measured by the 4-Meter Walk Test | About 6 weeks | |
Secondary | Physical performance | Physical performance measured by 30-Second Chair Stand Test (30-SCST) | About 6 weeks | |
Secondary | Physical performance | Physical performance measured by hand grip strength | About 6 weeks | |
Secondary | Body composition measured by Bioelectrical Impedance Analysis (BIA) | Body composition measured by Bioelectrical Impedance Analysis (BIA) | About 6 weeks | |
Secondary | Quality of life of patients assessed by QLQ-C30 | Quality of life of patients assessed by QLQ-C30 | About 6 weeks | |
Secondary | Intake assessed by a simple diet self-assessment tool (SDSAT) | Intake assessed by a simple diet self-assessment tool (SDSAT) | About 6 weeks | |
Secondary | Psychological status assessed by hospital anxiety and depression scale (HADS) | Psychological status assessed by hospital anxiety and depression scale (HADS) | About 6 weeks | |
Secondary | Number of participants with intervention-related adverse events | Number of participants with intervention-related adverse events | About 6 weeks | |
Secondary | Patients in the intervention group were interviewed about the compliance of the study | Patients in the intervention group were interviewed about the compliance of the study | About 6 weeks | |
Secondary | Patients in the intervention group were interviewed about the experience of the study | Patients in the intervention group were interviewed about the experience of the study | About 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |